Beam Therapeutics Inc. — fact timeline

Beam Therapeutics Inc. reported financial results for quarter ended March 31, 2026.

“On May 7, 2026, the Company issued a press release announcing its financial results for the quarter ended March 31, 2026.”

Beam Therapeutics Inc. terminated License Agreement with Bio Palette Co., Ltd. (effective 2026-03-02).

“Beam Therapeutics Inc. (the “Company”) and Bio Palette Co., Ltd. (“Bio Palette”) mutually terminated the License Agreement by and between the Company and Bio Palette dated March 27, 2019 (the “License Agreement”)”

Beam Therapeutics Inc. incurred term loan of up to $500 million with Sixth Street Lending Partners at 3-month Secured Overnight Financing Rate (SOFR) plus 6.50% (subject to a 1.00% f maturing February 24, 2033.

“On February 24, 2026 (the “Closing Date”), Beam Therapeutics Inc. (the “Company”) entered into a financing agreement (the “Financing Agreement”) with certain subsidiaries of the Company as guarantors party thereto, the lenders party thereto (the “Lenders”), and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders. The Financing Agreement provides for a senior secured term loan facility of up to $500 million (the “Credit Facility”), consisting of (i) an initial draw of $100 million on the Closing Date,”

Beam Therapeutics Inc. entered into Financing Agreement with Sixth Street Lending Partners, as administrative agent and collateral agent valued at $500 million (effective 2026-02-24).

“On February 24, 2026 (the “Closing Date”), Beam Therapeutics Inc. (the “Company”) entered into a financing agreement (the “Financing Agreement”) with certain subsidiaries of the Company as guarantors party thereto, the lenders party thereto (the “Lenders”), and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders.”

Beam Therapeutics Inc. entered into Standby License Agreement with Kobe University and Bio Palette Co., Ltd. (effective 2026-02-09).

“on February 9, 2026, the Company entered into a standby license agreement (the “Standby License Agreement”) with Kobe and Bio Palette.”

Beam Therapeutics Inc. completed a disposition involving Bristol-Myers Squibb Company for $255.1 million in closing cash consideration, plus the right to receive up to approximately $26.3 million in additional cash consideration (closed 2025-12-08).

“of Orbital common stock, which represented a fully diluted ownership stake of approximately 17%. At the closing of the Acquisition, such shares were cancelled and converted into $255.1 million in closing cash consideration, plus the right to receive up to approximately $26.3 million in additional cash consideration upon the release, if any, of certain escrows. The”

John Evans was appointed as Principal Financial and Accounting Officer at Beam Therapeutics Inc..

“Effective upon Ms. Burrell’s resignation, John Evans, the Company’s Chief Executive Officer and a member of the Company’s board of directors, was appointed Principal Financial and Accounting Officer of the Company.”

Terry-Ann Burrell resigned as Chief Financial Officer and Treasurer at Beam Therapeutics Inc..

“Terry-Ann Burrell notified Beam Therapeutics Inc. (the “Company”) of her decision to resign as Chief Financial Officer and Treasurer of the Company, effective August 9, 2024, to pursue other opportunities.”

Beam Therapeutics Inc. reported first quarter 2024 results: net income ($98.7 million), EPS ($1.21).

“Net loss was $98.7 million for the first quarter of 2024, or $1.21 per share, compared to $96.5 million for the first quarter of 2023, or $1.33 per share.”